STU3 Candidate

This page is part of the FHIR Specification (v1.8.0: STU 3 Draft). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

4.3.2.16621 HL7 v3 Value Set ActSubstanceAdminSubstitutionCode

This value set (http://hl7.org/fhir/ValueSet/v3-ActSubstanceAdminSubstitutionCode) is defined as part of HL7 v3. Related FHIR content: ActSubstanceAdminSubstitutionCode.

Summary

Defining URL:http://hl7.org/fhir/ValueSet/v3-ActSubstanceAdminSubstitutionCode
Name:ActSubstanceAdminSubstitutionCode
Definition:No Description Provided
OID:2.16.840.1.113883.1.11.16621 (for OID based terminology systems)
Source ResourceXML / JSON

This value set is used in the following places:


This value set includes codes from the following code systems:

 

This expansion generated 06 Dec 2016


This value set contains 9 concepts

Expansion based on http://hl7.org/fhir/v3/substanceAdminSubstitution version 2016-11-11

All codes from system http://hl7.org/fhir/v3/substanceAdminSubstitution

CodeDisplayDefinition
EequivalentDescription: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
ECequivalent compositionDescription: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
BCbrand compositionDescription: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
Ggeneric compositionDescription: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
TEtherapeutic alternativeDescription: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
TBtherapeutic brandDescription: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
TGtherapeutic genericDescription: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
FformularyDescription: This substitution was performed or is permitted based on formulary guidelines.
NnoneNo substitution occurred or is permitted.